Novel targets in solid tumors: MEK inhibitors

Wells A. Messersmith, Manuel Hidalgo, Michael Carducci, S. Gail Eckhardt

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


MAPK/ERK kinase (MEK) inhibitors constitute a promising class of novel targeted therapies. Although some of the initial clinical results with these compounds were disappointing, newer agents with more advantageous pharmacokinetic and pharmacodynamic properties have entered clinical trials. Partial responses have been seen in patients with advanced melanoma and pancreatic cancer, along with prolonged stable disease in several tumor types. Rash, diarrhea, edema, and visual disturbances have been common toxicities. With the recent finding that cell lines with B-raf mutations are exquisitely sensitive to these compounds, the possibility of genetic-based patient selection and indiviualized therapy has been raised. Whether these predictions will be borne out in clinical testing remains to be seen.

Original languageEnglish (US)
Pages (from-to)831-836
Number of pages6
JournalClinical Advances in Hematology and Oncology
Issue number11
StatePublished - Nov 1 2006


  • ERK
  • MAPK
  • MEK inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Novel targets in solid tumors: MEK inhibitors'. Together they form a unique fingerprint.

Cite this